行情

CRVS

CRVS

Corvus Pharms
NASDAQ

实时行情|Nasdaq Last Sale

2.745
-0.025
-0.90%
交易中 14:15 11/19 EST
开盘
2.800
昨收
2.770
最高
2.850
最低
2.710
成交量
9.87万
成交额
--
52周最高
8.10
52周最低
2.530
市值
8,010.84万
市盈率(TTM)
-1.7450
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRVS 新闻

  • 分析师:iPhone 11需求强劲 获得“巨大”成功
  • 新浪财经.13分钟前
  • 无论谁赢得下月大选 英国将卷入新一波债务洪流
  • 新浪美股.16分钟前
  • 美国科技巨头反击美国议员反垄断担忧 回应来了
  • 新浪美股.26分钟前
  • 麻烦不断!电子烟巨头Juul因针对青少年推销再遭起诉
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
+2.05%
制药与医学研究
+0.68%

热门股票

名称
价格
涨跌幅

CRVS 简况

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
展开

Webull提供Corvus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。